Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$19.2 - $25.14 $223,430 - $292,554
-11,637 Closed
0 $0
Q1 2018

May 11, 2018

SELL
$12.46 - $21.32 $20,733 - $35,476
-1,664 Reduced 12.51%
11,637 $248,000
Q4 2017

Feb 13, 2018

BUY
$11.37 - $16.4 $151,232 - $218,136
13,301
13,301 $168,000

Others Institutions Holding MYOV

About Myovant Sciences Ltd.


  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Shepherd Kaplan Krochuk, LLC Portfolio

Follow Shepherd Kaplan Krochuk, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shepherd Kaplan Krochuk, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Shepherd Kaplan Krochuk, LLC with notifications on news.